🤯 Picked by our AI, this stock rallied more than Nvidia this month, yielding 94% since MarchSee the stock

Acelyrin reports positive early trial results for TED therapy

EditorEmilio Ghigini
Published 03/20/2024, 07:16 AM
© Reuters.

LOS ANGELES - Acelyrin Inc. (NASDAQ:SLRN), a biopharmaceutical company specializing in immunology treatments, has announced promising early results from its Phase 1/2 trial for lonigutamab, a potential new therapy for thyroid eye disease (TED). The medication, a subcutaneously delivered monoclonal antibody targeting the IGF-1 receptor, showed rapid improvements in proptosis, clinical activity scores, and diplopia compared to placebo, with a favorable safety profile.

The trial data revealed that within three weeks of the first subcutaneous dose, patients experienced significant improvements. Specifically, 50% of patients in the first cohort and 67% in the second cohort saw a reduction in proptosis.

Clinical activity scores improved for all patients in the first cohort and 83% in the second cohort. Additionally, 25% of patients in the first cohort and 40% in the second cohort experienced improvements in diplopia, a condition of double vision.

Dr. Shao-Lee Lin, CEO of Acelyrin, expressed optimism regarding the potential of lonigutamab to offer a more convenient and safer treatment option for TED patients, given its subcutaneous administration and rapid response. The absence of serious adverse events, such as hyperglycemia or hearing impairment, further supports the therapy's favorable safety profile.

The trial is ongoing, with further data expected to be presented at future scientific meetings. Acelyrin plans to initiate a Phase 2b/3 trial in the second half of 2024, which is designed to be the first of two registrational trials for this condition.

TED is an autoimmune disease that can lead to eye bulging, difficulty closing eyelids, double vision, and potentially blindness. It is estimated that over 100,000 people in the United States suffer from this condition.

Acelyrin has decided not to host a fiscal year 2023 earnings call but will announce financial results in a press release and file the related 10-K report by April 1, 2024. A conference call to review the clinical data was held today, with a recording available on the company's website.

The information in this article is based on a press release statement from Acelyrin Inc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.